Introduction: Hepatic veno-occlusive disease (VOD, or sinusoidal obstruction syndrome) is a potentially fatal complication of stem cell transplantation (SCT). Severe VOD (sVOD) is usually characterized by multi-organ failure (MOF) and >80% mortality. Defibrotide (DF) is approved in the EU for the treatment of sVOD in SCT. We report the final results of a large, international compassionate use program (CUP; 1998-2009 in Europe, the US, Asia, and the Middle East. Methods: DF was provided on a compassionate basis or via single patient (pt) emergency-use requests post-SCT or chemo-/radiotherapy. Eligibility, DF use, safety, and outcomes were collected with case record forms. In the US, pts met Baltimore criteria for VOD and had MOF. At other sites, pts met Seattle or Baltimore, ultrasound, and/or histological criteria. Initial dosing recommendation was 10 mg/kg/d (4 divided doses/d IV) titrated up to 60 mg/kg/d based on tolerability/response. Following results of a US Phase 2 study, the recommended dose was 25 mg/kg/d. Treatment duration was up to investigators. Data included adverse events (AEs) and survival at Day+100 post-SCT or start of chemo-/ radiotherapy. Results: Safety/outcome data were submitted voluntarily for 710 pts receiving 1 DF dose. VOD developed post-SCT in 89% (71% allogeneic; 16% autologous; 2% missing), and postchemo-/radiotherapy in 11%. Median age was 25 (range, 0.2-70) years; 43% were <18 years.
The Kaplan-Meier (KM) estimate of Day+100 survival was 54%. The figure shows KM survival curve by dose group; in the 25 mg/kg/d group (the approved EU dose) estimated survival was 58% at Day+100 ( Figure 1 ). Conclusions: DF was generally well tolerated in this large CUP; AEs were typical for VOD pts. Consistent with prior studies, survival was 54% at Day+100. Background: AdV is associated with significant morbidity and mortality. No drug is currently approved for AdV. BCV is an orally available lipid-conjugate of cidofovir (CDV) that has demonstrated promise as preemptive therapy in allo HCT patients (pts) with asymptomatic AdV viremia (VL) in a Phase 2 study. The pilot portion of a Phase 3 BCV study for AdV (CMX001-304, AdVise Study; NCT02087306) was initiated in MAR2014. Preliminary results for 26 subjects enrolled through 15JUL2014 are described (data cut-off 12SEP2014). Methods: All subjects receive open-label BCV 100 mg ( 50 kg) or 2 mg/kg (< 50 kg) twice a week. Results: For the 26 subjects, median age ¼ 6.5 y (range: 0-29), 58% < 12 y; 20 allo HCT pts (16 with disseminated disease), 4 solid organ transplant pts and 2 chemotherapy pts; median VL in plasma by quantitative polymerase chain reaction (PCR) at baseline (BL) 4.8 log 10 c/mL (range: undetectable [< 2 log 10 ; < LOD] to > 10 log 10 ) (n ¼ 23); 46% were AdV positive in respiratory secretions, 58% in urine, 58% in stool by qualitative PCR; 42% (11/26) had prior IV CDV exposure. Median BCV treatment duration 54 days (range: 1 to 108). Suppression of plasma AdV VL to < LOD by quantitative PCR was 61% (14/23) at any time ontreatment and 52% (12/23) at last on-treatment value. Median change in plasma AdV VL from BL to nadir was -1.4 log 10 c/mL (range: -8.0 to 0.6), with 65% (15/23) achieving 3 log 10 decrease to nadir (or to < LOD). Individual plots of plasma AdV VL over time are shown in the figure. In subjects with positive qualitative AdV PCR at BL, 42% (5/12) cleared AdV in respiratory secretions, 33% (5/15) in urine and 27% (4/15) in stool. Six of the 11 subjects with prior IV CDV achieved AdV VL < LOD and one had > 2 log 10 decline at last on-treatment value. Treatment-related AEs requiring premature BCV discontinuation were limited to severe diarrhea (in two subjects). Among the 48 subjects enrolled through 19SEP2014, there were 17 deaths, including two of seven subjects with asymptomatic disease (29%), in 11 of 29 allo HCT subjects with disseminated AdV (38%) and four of 12 subjects with non-allo HCT disseminated AdV (33%), representing an overall mortality rate to-date of 35% (17/48), with a median duration of observation of 57 days for living pts. Safety and efficacy data from newly enrolled subjects will be included in the presentation. Conclusions: These preliminary results from 26 subjects enrolled in the pilot portion of AdVise show mortality rates of < 40% across subjects with limited and disseminated AdV and across populations with varying identified risk factors (HCT, SOT, other); these are lower mortality rates than those in the literature for disseminated disease. AdV viremia was suppressed to undetectable in over half of enrolled subjects. No new safety concerns were identified in this complex patient population. These data support progression to definitive Phase 3 BCV study for AdV. Introduction: Severe hepatic veno-occlusive disease (VOD, also called sinusoidal obstruction syndrome) with multiorgan failure (MOF) is a life-threatening complication of hematopoietic stem cell transplant (HSCT), with a mortality rate of >80%. Defibrotide has a protective effect on injured endothelium and restores thrombo-fibrinolytic balance. In severe VOD, defibrotide improves complete response (CR) rates and survival at Day+100 post-HSCT, with a favorable safety profile. In the EU, defibrotide is approved for treatment of severe hepatic VOD in HSCT therapy in adults and children. In the US, there are no approved therapies for VOD; however, defibrotide is available through an expanded access, protocol-directed treatment IND (T-IND). The T-IND gathers data on safety/ efficacy of defibrotide in patients (pts) with severe and non-severe VOD post-HSCT, as well as post-chemotherapy (CT) alone. Methods: The original T-IND protocol required VOD diagnosed by Baltimore criteria (total bilirubin 2.0 mg/dL with 2 of hepatomegaly, ascites, or 5% weight gain) with MOF (renal and/or pulmonary failure) following HSCT; the study was amended to include non-severe VOD (defined as no MOF) post-HSCT or post-CT. Exclusion criteria include clinically significant bleeding or need for >1 vasopressor. Defibrotide was given as a 2-hour infusion at 6.25 mg/kg IV q6h (25 mg/kg/d) for a recommended 21 days. Results: This interim safety analysis update is based on 612 pts enrolled from December 2007 to December 2013 (including 99 in 2013) who received 1 defibrotide dose. Median patient age was 12 years (range <0.1e69).
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Overall, 1 treatment emergent adverse event (AE) was reported in 454 pts (74.2%). Of these, 138 pts (22.5%) had AEs possibly, probably, or definitely related to defibrotide. Related AEs in >2.0% included pulmonary hemorrhage (4.7%), gastrointestinal hemorrhage (3.6%), epistaxis (3.1%), and hypotension (2.8%). Serious AEs (SAEs) were reported by 368 pts (60.1%) and most were assessed as not related to defibrotide; 82 pts (13.4%) had an SAE at least possibly related to study treatment, most commonly pulmonary hemorrhage (3.9%) and gastrointestinal hemorrhage (2.9%). AEs leading to death occurred in 254 pts (41.5%); these AEs were deemed possibly related to study medication in only 17 pts (2.8%).
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